KAREN MARAVI: Open Payments
NPI 1093578759 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,176 in 68 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,270 · 2025 $1,176
Food & beverage: $1,176
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 26 | $402 |
| AstraZeneca Pharmaceuticals LP | 14 | $310 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $143 |
| Lilly USA, LLC | 10 | $123 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| ABBVIE INC. | 1 | $27 |
| Almatica Pharma LLC | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
Products named: FARXIGA, Kerendia, Wegovy, AIRSUPRA, MOUNJARO, Ozempic, BREZTRI, JARDIANCE.
Industry payments across TX — which companies pay providers there.
